Capital Markets Day 2017

Capital Markets Day 2017

Bavarian Nordic - Capital Markets Day

Bavarian Nordic hosted a capital markets day for investors and analysts on Thursday, September 21, 2017 in New York City.

The management of Bavarian Nordic, collaborators from the National Cancer Institute and key opinion leaders within the field of oncology and infectious diseases presented  the company's business and future plans and opportunities.


Speakers / AGENDA


Welcoming remarks and corporate update

Paul Chaplin, Ph.D.
President & Chief Executive Officer of Bavarian Nordic


Therapeutic cancer vaccines landscape and the role of vaccines in combination

Douglas McNeel M.D., Ph.D.
Associate Professor in the Department of Medicine, division of Hematology/Oncology, at the University of Wisconsin-Madison


PROSTVAC Phase 3 review - Emerging data from PROSTVAC in combination with checkpoints - CV301 update - how we can succeed

James Gulley, M.D., Ph.D.
Chief, Genitourinary Malignancies Branch, Senior Investigator, Head, Immunotherapy Section, Director, Medical Oncology Service, CCR Office of the Clinical Director, NCI. Principal Investigator on PROSTVAC Phase 3 study


Emerging preclinical opportunities

Hubertus Hochrein, Ph.D.
Senior Director of Research, Bavarian Nordic


Pipeline review and clinical update

Christopher Heery, M.D.
Chief Medical Officer of Bavarian Nordic


Rolf Sass Sørensen
Vice President Investor Relations (EU)
Tel: +45 61 77 47 43

Seth Lewis
Vice President Investor Relations (US)
Tel: +1 978 341 5271